Produced in collaboration with the Aplastic Anemia & MDS International Foundation.
Supported by educational grants from Bristol Myers Squibb, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Novartis Pharmaceuticals Corporation, and Taiho.
Patients with myelodysplastic syndromes (MDS) often experience feelings of anger, stress, and anxiety when diagnosed and throughout their disease course. Maintaining open communication among patients, caregivers, and the healthcare team is essential for managing treatment.
To get help, watch this free educational presentation led by Dr. Mikkael Sekeres. “Establishing Goals of Therapy While Managing Myelodysplastic Syndromes,” is an hour-long interactive discussion of MDS and potential treatment approaches.
Hear MDS patients talk about their lived experiences, and develop a clearer understanding of treatment options, side effects, quality-of-life changes, and financial impacts associated with MDS.
An AAMDSIF advocate l discusses how to improve communication with your care team to set realistic expectations for treatment and accessing resources available to you and your family.
Management options for MDS including supportive vs active care, indications for active care, and clinical trials will also be discussed.
Mikkael Sekeres MD, MS
Professor of Medicine, University of Miami, Sylvester Cancer Center
Mikkael Sekeres, MD, MS, is professor of medicine and chief of the Division of Hematology in the Department of Medicine and physician liaison for the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine in Florida. His research focuses on patients with myelodysplastic syndrome and older adults with acute myeloid leukemia, and he has been the national and international primary study investigator on several trials. Dr Sekeres is the author or co-author of over 350 manuscripts and 650 abstracts published in leading journals. He has also authored 7 books, including When Blood Breaks Down: Life Lessons from Leukemia. Dr Sekeres is chair of the medical advisory board of the Aplastic Anemia and Myelodysplastic Syndrome International Foundation.
Hetty Carraway MD, MBA
Vice Chair, Strategy and Enterprise Development; Associate Professor, Cleveland Clinic; Taussig Cancer Center, Cleveland Clinic
Hetty Caraway, MD, MBA, FACP, is associate professor of medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, vice chair of strategy and enterprise development at the Taussig Cancer Institute in the Division of Hematologic Oncology and Blood Disorders, and director of the Leukemia Program at the Cleveland Clinic in Ohio. Her research is focused on experimental therapeutics of acute leukemias and myeloproliferative diseases. Dr Carraway has co-authored numerous peer-¬reviewed publications, review articles, editorials, abstracts, and book chapters. She is nationally sought for her expertise in hematologic malignancies. Dr Carraway is an active member of numerous professional organizations, including the American Society of Hematology.
MDS Patient and Advocate
Ruth Cuadra was originally diagnosed with aplastic anemia in 1996 when a routine checkup showed that her blood counts were at life-threatening low levels. She was treated with an immunosuppressant, but could never get back to normal blood counts. In 1998, Ruth’s only option was supportive care until her myelodysplastic syndrome (MDS) became leukemia or transplant. Because she had a young family and an available donor, she chose transplant and the chance for a cure, despite the risks. Eventually Ruth was found to have chromosomal abnormalities and re-diagnosed with MDS at age 43. Since her recovery, she has tried to give something back to those who helped save her life, including the Aplastic Anemia & MDS International Foundation (AAMDSIF) by serving on its executive board for 5 years.
Joan D. Powell
Interview Participant - MDS Patient and Advocate
Interview Participant - MDS Patient